MedCity News July 22, 2021
Merck and Evidation Health launched a study to see if data from smartphones and wearables could be used to detect and monitor the treatment of Alzheimer’s Disease.
Merck is partnering with a digital health startup to see if smartphone data can be used to identify digital endpoints for Alzheimer’s drug development.
The study will use a research platform developed by Evidation Health, a startup that pulls health data from smartphones and wearable devices for virtual studies.
This study will be used to determine if digital measures could be used to detect and monitor the treatment of Alzheimer’s disease in its early stages.
Dr. Michael Egan, Merck’s vice president of Neuroscience Global Clinical Development, said in a news release that the...
Today's Sponsors
Today's Sponsor